Incentive changes name to Gambro
Gambro is a global company in medical-technology and healthcare services with leading positions in renal care - dialysis products and renal care services - cardiovascular-surgery products and blood component technology. Gambro* has annual revenues of SEK 19 billion, and 17.000 employees in 90 subsidiaries in 26 countries. The operations include the following four business areas. Dialysis Products - Gambro Renal Products - is responsible for development, production, marketing and sales of dialysis products worldwide, and also renal care services with 3.000 patients in Europe and Asia. Total sales amount to approximately SEK 8 billion. Renal Care Services - Gambro Healthcare - is responsible for dialysis clinics operations with 33.000 patients in North and South America, in addition to marketing and sales of dialysis products in markets in North and South America. Total sales are approximately SEK 9 billion. Cardiopulmonary Care - COBE CV - manufactures cardiovascular-surgery products, primarily for markets in North and South America, Europe and the Asia-Pacific region, with sales of approximately SEK 1 billion. Blood Component Technology - COBE BCT - covers products for the separation and handling of blood components, with major markets in North and South America, Europe and the Asia-Pacific region and sales of approximately SEK 1 billion. o is a Swedish listed company (GAMB) with about 70.000 shareholders. * After closing the selling of the subsidiary MacGREGOR. For further information: Bengt Modéer, Senior Vice President, Corporate Communications, +46-8-613 65 00, +46-70-513 65 33 Gambro is an international medical-technology group with revenues of approximately SEK 22 billion and about 18,000 employees in some 40 countries.